The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland

NCT06889948 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Kidney Failure
Paraproteinemias
Glomerulonephritis

Interventions

DRUG: Daratumumab

Sponsor

Helsinki University Central Hospital

Collaborators

[object Object]